Literature DB >> 10657648

Transfer of immune complexes from erythrocyte CR1 to mouse macrophages.

M L Reinagel1, R P Taylor.   

Abstract

We are developing a potential therapeutic approach for removing pathogens from the circulation of primates in which the pathogen is bound to the complement receptor (CR1) on E using a bispecific mAb complex, a heteropolymer (HP). We have used mAb this approach to demonstrate that cleared prototype pathogens are localized to, phagocytosed in, and destroyed in the liver. Extension of this work to a clinical setting will require a detailed understanding of the mechanism by which the E-bound immune complex substrates are transferred to fixed tissue macrophages in the liver, the transfer reaction. Therefore, we examined an in vitro system to study this process using bacteriophage phiX174 as a model pathogen. E containing phiX174 (bound via an anti-CR1/anti-phiX174 HP) were incubated with P388D1 murine macrophages, and the two cell types were separated by centrifugation through Ficoll. Both E and macrophages were then probed and analyzed by RIA or flow cytometry. The results indicate that all three components of the E-bound IC (phiX174, HP, and CR1) were removed from the E and internalized by the macrophages. We found that transfer requires the Fc portion of IgG, because little transfer of phiX174 occurs when it is bound to E CR1 using a HP containing only Fab fragments. These findings, taken in the context of other studies, suggest a general mechanism for the transfer reaction in which Fc receptors facilitate close juxtaposition of the macrophage to the E-bound IC which then allows a macrophage-associated protease to cleave CR1. The released IC are then internalized and processed by the macrophages.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10657648     DOI: 10.4049/jimmunol.164.4.1977

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  The role of complement in danger sensing and transmission.

Authors:  Jörg Köhl
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  Complement receptor activity of recombinant porcine CR1-like protein expressed in a eukaryotic system.

Authors:  Wei Yin; Xiaoming Wei; Junbing Jiang; Kuohai Fan; Junxing Zhao; Na Sun; Zhiwei Wang; Yaogui Sun; Haili Ma; Xin Zhao; Hongquan Li
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

3.  A transgenic mouse model for studying the clearance of blood-borne pathogens via human complement receptor 1 (CR1).

Authors:  A Repik; S E Pincus; I Ghiran; A Nicholson-Weller; D R Asher; A M Cerny; L S Casey; S M Jones; S N Jones; N Mohamed; L B Klickstein; G Spitalny; R W Finberg
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

4.  Both Fcgamma and complement receptors mediate transfer of immune complexes from erythrocytes to human macrophages under physiological flow conditions in vitro.

Authors:  A L Hepburn; J C Mason; S Wang; C J Shepherd; O Florey; D O Haskard; K A Davies
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

5.  Antibody CR1-2B11 recognizes a non-polymorphic epitope of human CR1 (CD35).

Authors:  C-H Chen; I Ghiran; F J M Beurskens; G Weaver; J A Vincent; A Nicholson-Weller; L B Klickstein
Journal:  Clin Exp Immunol       Date:  2007-06       Impact factor: 4.330

Review 6.  Comparative functional evolution of human and mouse CR1 and CR2.

Authors:  Amanda C Jacobson; John H Weis
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

7.  Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor.

Authors:  Rashmi Sharma; Huiwu Zhao; Fetweh H Al-Saleem; Ahmed Syed Ubaid; Rama Devudu Puligedda; Andrew T Segan; Margaret A Lindorfer; Rodney Bermudez; Md Elias; Sharad P Adekar; Lance L Simpson; Ronald P Taylor; Scott K Dessain
Journal:  Mol Immunol       Date:  2013-11-01       Impact factor: 4.407

8.  Modern Technologies for Creating Synthetic Antibodies for Clinical application.

Authors:  S M Deyev; E N Lebedenko
Journal:  Acta Naturae       Date:  2009-04       Impact factor: 1.845

9.  Loss of complement regulatory proteins on red blood cells in mild malarial anaemia and in Plasmodium falciparum induced blood-stage infection.

Authors:  Damian A Oyong; Jessica R Loughland; Arya SheelaNair; Dean Andrew; Fabian D L Rivera; Kim A Piera; Timothy William; Matthew J Grigg; Bridget E Barber; Ashraful Haque; Christian R Engwerda; James S McCarthy; Nicholas M Anstey; Michelle J Boyle
Journal:  Malar J       Date:  2019-09-18       Impact factor: 2.979

Review 10.  Complement and systemic lupus erythematosus.

Authors:  Mark J Walport
Journal:  Arthritis Res       Date:  2002-05-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.